Unicycive Therapeutics, Inc. Class Action Lawsuit
Company: Unicycive Therapeutics, Inc.
Ticker: (NASDAQ) UNCY
Class Action Period: December 29, 2025 - June 29, 2026
See If You Qualify For Monetary Reward
How to Check Whether You May Be Eligible in the Unicycive Therapeutics, Inc. Class Action
CLASS ACTION PERIOD
December 29, 2025 - June 29, 2026
Allegations
The complaint filed against Unicycive Therapeutics, Inc. alleges the company made statements that were materially false and/or misleading and/or failed to disclose that: (1) the Company had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Eligibility
To be eligible for the lawsuit, you must have experienced a loss on Unicycive Therapeutics, Inc. shares purchased within the class period specified above.
Lead Plaintiff Deadline
If you suffered a loss in Unicycive Therapeutics, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until November 2, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How can Unicycive Therapeutics, Inc. (NASDAQ: UNCY) investors check whether their transactions may be relevant?
Investors who purchased shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) during the class period (December 29, 2025 - June 29, 2026) may submit their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information before the deadline
The lead plaintiff deadline for this case is November 2, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
- Who is eligible for the Unicycive Therapeutics, Inc. lawsuit?
Anyone who bought shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) during December 29, 2025 - June 29, 2026 and suffered financial losses may be eligible.
- What is the lead plaintiff deadline in the Unicycive Therapeutics, Inc. case?
The lead plaintiff deadline for the Unicycive Therapeutics, Inc. lawsuit is November 2, 2026. Investors who wish to seek appointment as lead plaintiff should act quickly to avoid missing this deadline. No action is required before that date to remain an absent class member.
- What is the class period for Unicycive Therapeutics, Inc.?
The class period for Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is December 29, 2025 - June 29, 2026, during which investors may have been affected by alleged misconduct.
- Could I still be eligible for the Unicycive Therapeutics, Inc. lawsuit if I sold my shares?
Yes. Investors who purchased Unicycive Therapeutics, Inc. shares during December 29, 2025 - June 29, 2026 may still qualify, even if they sold their shares later.
- How much compensation can I receive from the Unicycive Therapeutics, Inc. lawsuit?
Compensation depends on the total losses and the final settlement. Eligible investors in the Unicycive Therapeutics, Inc. case may receive a portion of the recovery.
- Do I need to pay to participate in the Unicycive Therapeutics, Inc. case?
No. Most securities fraud cases are handled on a contingency basis, meaning there are generally no upfront attorney’s fees, and attorney’s fees are collected only if there is a recovery.
- Will I need to appear in court for the Unicycive Therapeutics, Inc. lawsuit?
In most cases, investors do not need to appear in court. The legal team manages the Unicycive Therapeutics, Inc. case on behalf of participants.
- What documents are required for the Unicycive Therapeutics, Inc. lawsuit?
To participate in the Unicycive Therapeutics, Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.
- What happens after I submit my trade information for Unicycive Therapeutics, Inc.?
After submission, your details for the Unicycive Therapeutics, Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.
- Is this legal advice for the Unicycive Therapeutics, Inc. lawsuit?
No, this page provides information about the Unicycive Therapeutics, Inc. case and does not constitute legal advice or create an attorney-client relationship.
- Why should I act quickly on the Unicycive Therapeutics, Inc. case?
The lead plaintiff deadline for the Unicycive Therapeutics, Inc. lawsuit is November 2, 2026. Investors who wish to seek appointment as lead plaintiff must apply by that date.
EXPLORE MORE CASES
Intuit Inc.
INTU
Intuit Inc. (INTU) Securities Class Action Lawsuit Update
Lead Plaintiff Deadline: September 8, 2026
Class Period: February 25, 2025 - June 1, 2026
Wise Group plc
WSE
Wise Group plc WSE Securities Class Action Lawsuit Update
Lead Plaintiff Deadline: September 29, 2026
Class Period: May 11, 2026 - July 23, 2026